Author(s):
Shikha Virk, Anshul Sharma, Rupinder Sodhi, Onkar Bedi, Sunny Dhiman
Email(s):
sdsdhiman1@gmail.com
DOI:
10.52711/0974-360X.2026.00483 
Address:
Shikha Virk1,2, Anshul Sharma3, Rupinder Sodhi4, Onkar Bedi5, Sunny Dhiman6*
1Chitkara College of Pharmacy, Chitkara University, Rajpura,Punjab, India.
2Department of Pharmacology, Chandigarh College of Pharmacy, CGC Landran Mohali, Punjab 140307 India.
3Department of Pharmacognosy, Chandigarh College of Pharmacy, CGC Landran Mohali, Punjab 140307 India.
4Department of Pharmacology Chandigarh College of Pharmacy, CGC Landran Mohali, Punjab 140307 India.
5Chitkara College of Pharmacy, Chitkara University, Rajpura,Punjab, India.
6Department of Pharmacology Chandigarh College of Pharmacy, CGC Landran Mohali, Punjab 140307 India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 7,
Year - 2026
ABSTRACT:
CVDs remain the uppermost disorder of mankind and the number of cases is unceasingly growing at unaccustomed rates. For instance; Myocardial hypertrophy, Heart failure, sudden cardiac arrest, MI, and so on. TLR plays a vital role in heart diseases and its family member TLR4 possesses a huge role in cardiac hypertrophy signaling. In this review, we compiled the various characteristics of TLR4 involving signal transduction of cardiac hypertrophy, its co-receptors, and ligand’s role in cardiac hypertrophy. A detailed literature search was accomplished using multiple online search engines like Google scholar and Pub med with regards to the available research and review accounts on TLR4 role in Hypertrophic Cardiomyopathy. Activities of Toll-like receptor 4 were selected reporting the significant addition from all the articles. The reviewed reports confirmed the TLR4 role in triggering myocardial hypertrophy.
Cite this article:
Shikha Virk, Anshul Sharma, Rupinder Sodhi, Onkar Bedi, Sunny Dhiman. Unveiling the Possible Role of Toll-like Receptors in Myocardial Hypertrophy. Research Journal of Pharmacy and Technology. 2026;19(7):3401-7. doi: 10.52711/0974-360X.2026.00483
Cite(Electronic):
Shikha Virk, Anshul Sharma, Rupinder Sodhi, Onkar Bedi, Sunny Dhiman. Unveiling the Possible Role of Toll-like Receptors in Myocardial Hypertrophy. Research Journal of Pharmacy and Technology. 2026;19(7):3401-7. doi: 10.52711/0974-360X.2026.00483 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-7-70
REFERENCE:
1. Mukherjee S, Karmakar S, Babu SPS. TLR2 and TLR4 mediated host immune responses in major infectious diseases: a review. Brazilian Journal of Infectious Diseases. 2016; 20(2): 193-204. 10.1016/j.bjid.2015.10.011
2. Wicherska-Pawłowska K, Wróbel T, Rybka J. Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs) in innate immunity. TLRs, NLRs, and RLRs ligands as immunotherapeutic agents for hematopoietic diseases. International Journal of Molecular Sciences. 2021; 22(24): 13397. 10.3390/ijms222413397
3. Xiao Z, Kong B, Yang H, Dai C, Fang J, Qin T, et al. Key player in cardiac hypertrophy, emphasizing the role of toll-like receptor 4. Frontiers in Cardiovascular Medicine. 2020; 7: 579036. 10.3389/fcvm.2020.579036
4. Asami J, Shimizu T. Structural and functional understanding of the toll‐like receptors. Protein Science. 2021; 30(4): 761-72. 10.1002/pro.4043
5. Pirianov G, Waddington SN, Lindstrom TM, Terzidou V, Mehmet H, Bennett PR. The cyclopentenone 15-deoxy-Δ12, 14-prostaglandin J2 delays lipopolysaccharide-induced preterm delivery and reduces mortality in the newborn mouse. Endocrinology. 2009; 150(2): 699-706. 10.1210/en.2008-1178
6. Ullah MO, Sweet MJ, Mansell A, Kellie S, Kobe B. TRIF-dependent TLR signaling, its functions in host defense and inflammation, and its potential as a therapeutic target. Journal of Leucocyte Biology. 2016; 100(1): 27-45. 10.1189/jlb.2RI1115-531R
7. Saulman C. Acute mechanical circulatory support in the cardiovascular ICU: Investigating the effects of an interactive Cardiovascular Dynamics Simulation Program on Nursing Clinical Judgment. 2024. https://doi.org/10.18297/etd/4383
8. Rengo G. The adrenergic system in cardiovascular physiology and pathophysiology: Frontiers Media SA; 2016. 10.3389/fphys.2014.00356
9. Hua F, Ha T, Ma J, Li Y, Kelley J, Gao X, et al. Protection against myocardial ischemia/reperfusion injury in TLR4-deficient mice is mediated through a phosphoinositide 3-kinase-dependent mechanism. The Journal of Immunology. 2007; 178(11): 7317-24. 10.4049/jimmunol.178.11.7317
10. Dabbaghi MM, Soleimani Roudi H, Safaei R, Baradaran Rahimi V, Fadaei MR, Askari VR. Unveiling the Mechanism of Protective Effects of Tanshinone as a New Fighter Against Cardiovascular Diseases: A Systematic Review. Cardiovascular Toxicology. 2024; 24(12): 1467-509. 10.1007/s12012-024-09921-x
11. Zhang Y, Wu J, Dong E, Wang Z, Xiao H. Toll-like receptors in cardiac hypertrophy. Frontiers in Cardiovascular Medicine. 2023; 10: 1143583. 10.3389/fcvm.2023.1143583
12. Han J, Zou C, Mei L, Zhang Y, Qian Y, You S, et al. MD2 mediates angiotensin II-induced cardiac inflammation and remodeling via directly binding to Ang II and activating TLR4/NF-κB signaling pathway. Basic research in cardiology. 2017; 112: 1-15. 10.1007/s00395-016-0599-5
13. Sumneang N, Oo TT, Singhanat K, Maneechote C, Arunsak B, Nawara W, et al. Inhibition of myeloid differentiation factor 2 attenuates cardiometabolic impairments via reducing cardiac mitochondrial dysfunction, inflammation, apoptosis and ferroptosis in prediabetic rats. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2022; 1868(2): 166301. 10.1016/j.bbadis.2021.166301
14. Shen CJ, Kong B, Shuai W, Liu Y, Wang GJ, Xu M, et al. Myeloid differentiation protein 1 protected myocardial function against high‐fat stimulation induced pathological remodelling. Journal of Cellular and Molecular Medicine. 2019; 23(8): 5303-16. 10.1111/jcmm.14407
15. Shen C, Yang S, Wu N, Jian W, Du T, Chu H, et al. Overexpression of MD1 ameliorates pathological myocardial remodeling in diabetic cardiomyopathy by TLR4/STAT3 signaling pathway. Molecular and Cellular Endocrinology. 2024; 592: 112315. 10.1016/j.mce.2024.112315
16. Jiang X, Kong B, Shuai W, Shen C, Yang F, Fu H, et al. Loss of MD1 exacerbates myocardial ischemia/reperfusion injury and susceptibility to ventricular arrhythmia. European Journal of Pharmacology. 2019; 844: 79-86. https://doi.org/10.1016/j.ejphar.2018.11.025
17. Bhattacharyya S, Varga J. Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy. Immunology letters. 2018; 195: 9-17. 10.1016/j.imlet.2017.09.011
18. Georgopoulos C, Welch W. Role of the major heat shock proteins as molecular chaperones. Annual review of cell biology. 1993; 9(1): 601-34. 10.1146/annurev.cb.09.110193.003125
19. Ferat-Osorio E, Sánchez-Anaya A, Gutiérrez-Mendoza M, Boscó-Gárate I, Wong-Baeza I, Pastelin-Palacios R, et al. Heat shock protein 70 down-regulates the production of toll-like receptor-induced pro-inflammatory cytokines by a heat shock factor-1/constitutive heat shock element-binding factor-dependent mechanism. Journal of Inflammation. 2014; 11: 1-12. 10.1186/1476-9255-11-19
20. Kumar S, Sharma V, Yadav S. TLR4 Targeting: A Promising Therapeutic Approach Across Multiple Human Diseases. Current Protein and Peptide Science. 2024. 10.2174/0113892037324425241018061548
21. Singh MK, Shin Y, Ju S, Han S, Choe W, Yoon K-S, et al. Heat shock response and heat shock proteins: Current understanding and future opportunities in human diseases. International Journal of Molecular Sciences. 2024;25(8):4209. 10.3390/ijms25084209
22. Kristian RA, Sandhika W. Expression level of HSP70 and COX-2 in breast cancer proliferation in Dr. Soetomo general hospital, Surabaya, Indonesia. Research Journal of Pharmacy and Technology. 2022;15(4):1636-40. 10.52711/0974-360X.2022.00273
23. Yoon S, Kim M, Min H-K, Lee Y-U, Kwon D-H, Lee M, et al. Inhibition of heat shock protein 70 blocks the development of cardiac hypertrophy by modulating the phosphorylation of histone deacetylase 2. Cardiovascular Research. 2019; 115(13): 1850-60. 10.1093/cvr/cvy317
24. Dhevi R, Gayathri K. Therapeutic Herbal Plants: A Review of Selected Animal Models for Coronary Heart Disease. Research Journal of Pharmacy and Technology. 2018; 11(11): 5197-204. 10.5958/0974-360X.2018.00949.6
25. Kee HJ, Eom GH, Joung H, Shin S, Kim J-R, Cho YK, et al. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy. Circulation research. 2008; 103(11): 1259-69. 10.1161/01.RES.0000338570.27156.84
26. Khare S, Chatterjee T, Gupta S, Patel A. Molecular Docking of Andrographoilde and HDAC2 inhibitor an approach to manage for Beta Thalassemia. Research Journal of Pharmacy and Technology. 2023; 16(9): 4143-7. 10.52711/0974-360X.2023.00678
27. Raucci A, Di Maggio S, Scavello F, D’Ambrosio A, Bianchi ME, Capogrossi MC. The Janus face of HMGB1 in heart disease: a necessary update. Cellular and Molecular Life Sciences. 2019; 76: 211-29. 10.1007/s00018-018-2930-9
28. Arif R, Jaffat HS. Assessment of procollagen 111N terminal peptide level in rats undergo CCl4 and bile duct ligation. Research Journal of Pharmacy and Technology. 2017; 10(7): 2132-5. 10.5958/0974-360X.2017.00374.2
29. Wang M, Gauthier A, Daley L, Dial K, Wu J, Woo J, et al. The role of HMGB1, a nuclear damage-associated molecular pattern molecule, in the pathogenesis of lung diseases. Antioxidants and Redox Signaling. 2019; 31(13): 954-93. 10.1089/ars.2019.7818
30. Gaba SS. Septic shock. Research Journal of Pharmacy and Technology. 2014;7(11):11.
31. Cai J, Wen J, Bauer E, Zhong H, Yuan H, Chen AF. The role of HMGB1 in cardiovascular biology: danger signals. Antioxidants and redox signaling. 2015; 23(17): 1351-69. 10.1089/ars.2015.6408
32. Harun NH, Mohamad MF. The immunomodulatory effects of Zingiber officinale (ginger): A systematic review. Research Journal of Pharmacy and Technology. 2022; 15(8): 3776-81. 10.52711/0974-360X.2022.00634
33. Wahid A, Chen W, Wang X, Tang X. High-mobility group box 1 serves as an inflammation driver of cardiovascular disease. Biomedicine and Pharmacotherapy. 2021; 139: 111555. https://doi.org/10.1016/j.biopha.2021.111555
34. Ayoub BM. Multifaceted repurposing of Flozins, Glitazones, Gliptins and GLP-1 agonists as potential Pluritherapeutic agents. Research Journal of Pharmacy and Technology. 2020; 13(1): 498-504. 10.5958/0974-360X.2020.00096.7
35. Black AP. A Novel Platform for Multiplexed N-glycoprotein Biomarker Discovery for Hepatocellular Carcinoma by Antibody Panel Based N-glycan Imaging. 2020. 10.1021/acs.analchem.9b01445
36. Priya SL, Prema KK. Screening and isolation of fibrinolytic enzymes from bacteria using agrowaste for thrombolytic treatment. Research Journal of Pharmacy and Technology. 2019; 12(4): 1963-6. 10.5958/0974-360X.2019.00328.7
37. Chen J, Wu L, Li Y. FGL1 and FGL2: emerging regulators of liver health and disease. Biomarker Research. 2024;12(1):53. 10.1186/s40364-024-00601-0
38. Salah RS, Ahmed HH, Abd-Allah SH, Hassan RE, Khalil WK, Abd-Rabou AA, et al. The anti-epileptic efficiency of mesenchymal stem cells against pilocarpine model of acute epilepsy. Research Journal of Pharmacy and Technology. 2021; 14(3): 1255-66. 10.5958/0974-360X.2021.00223.7
39. Yu L, Wang L, Chen S. Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis? Cellular and Molecular Life Sciences. 2012; 69: 935-49. 10.1007/s00018-011-0864-6
40. Takano H, Zou Y, Hasegawa H, Akazawa H, Nagai T, Komuro I. Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxidants and Redox Signaling. 2003; 5(6): 789-94. 10.1089/152308603770380098
41. Jaiswal A, Semwal BC, Singh S. A compressive review on novel molecular target of diabetic nephropathy. Research Journal of Pharmacy and Technology. 2022; 15(3): 1398-404. 10.52711/0974-360X.2022.00233
42. Chakraborti S, Chakraborti T. Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: a brief overview. Cellular signalling. 1998; 10(10): 675-83. 10.1016/s0898-6568(98)00014-x
43. Reddy S, Rao GM, Marathe A, Kamath S. Whey preparation as an adjuvant to minimise the Intestinal inflammatory status in mucositis rat model. Research Journal of Pharmacy and Technology. 2023; 16(12): 5860-6. 10.52711/0974-360X.2023.00949
44. Jadli AS, Parasor A, Gomes KP, Shandilya R, Patel VB. Exosomes in cardiovascular diseases: pathological potential of nano-messenger. Frontiers in cardiovascular medicine. 2021; 8: 767488. 10.3389/fcvm.2021.767488
45. Wibowo BP, Kalim H, Khotimah H, Sujuti H, Rukmigarsari E. TLR4/NF-kB/β-Catenin/TGF-β pathways in Salmonella AvrA related-Colorectal Cancer Tumorigenesis. Research Journal of Pharmacy and Technology. 2024; 17(6): 2597-604. 10.52711/0974-360X.2024.00406
46. Gao W, Wang H, Zhang L, Cao Y, Bao J-Z, Liu Z-X, et al. Retinol-binding protein 4 induces cardiomyocyte hypertrophy by activating TLR4/MyD88 pathway. Endocrinology. 2016; 157(6): 2282-93. 10.1210/en.2015-2022
47. Govindaraj J, Govindaraj K, Jayesh SR, Padmavathy K, Ramalingam M, Vidyarekha U. Role of Adipokines in Obesity and Obesity related Metabolic Disorders. Research Journal of Pharmacy and Technology. 2021; 14(8): 4261-4. 10.52711/0974-360X.2021.00739
48. Wu Y, Zou Y, Song C, Cao K, Cai K, Chen S, et al. The role of serine/threonine protein kinases in cardiovascular disease and potential therapeutic methods. Biomedicine and Pharmacotherapy. 2024; 177: 117093. https://doi.org/10.1016/j.biopha.2024.117093
49. Hendrawan VF, Wulansari D, Oktanella Y. Effectiveness of chlorogenic acid supplementation on VEGF serum and placental MAP kinase expression in carbon Black-Exposed pregnant rattus norvegicus. Research Journal of Pharmacy and Technology. 2018;11(5):1830-4. 10.5958/0974-360X.2018.00340.2
50. Li D, Guo Y-y, Cen X-f, Qiu H-l, Chen S, Zeng X-f, et al. Lupeol protects against cardiac hypertrophy via TLR4-PI3K-Akt-NF-κB pathways. Acta Pharmacologica Sinica. 2022; 43(8): 1989-2002. 10.1038/s41401-021-00820-3
51. Tambe V, Pujari R, Karnik A, Dongre P. Pterostilbene: A review on its pharmacological activities. Research Journal of Pharmacy and Technology. 2023; 16(11): 5514-21. 10.52711/0974-360X.2023.00892
52. Marcelo KL, Means AR, York B. The Ca2+/calmodulin/CaMKK2 axis: nature's metabolic CaMshaft. Trends in Endocrinology and Metabolism. 2016;27(10):706-18. 10.1016/j.tem.2016.06.001
53. Ko CY, Smith CE, Grandi E. Calcium-dependent signaling in cardiac myocytes. Cardiovascular signaling in health and disease. 2022:3-37. 10.1007/978-3-031-08309-9_1
54. Akhmetova M, Nigmatullina R, Mindubayeva F, Tykezhanova G. The effect of adrenaline on the contractility of the Right Ventricular Myocardium in rat pups with altered serotonin concentration in ontogenesis. Research Journal of Pharmacy and Technology. 2022; 15(5): 2010-6. 10.52711/0974-360X.2022.00333
55. Rink L, Hebel T, Fukumot J. Sepsis and signal transduction pathway: cross-talk TLR4/MyD88/TRIF. Am J BioMed. 2015; 3(4): 150-63. 10.18081/ajbm/2333-5106/014-04/150-163
56. Nayak Y, Jayashree B, Unnikrishnan M. Benzopyran-4-one is an ideal pharmacophore for lead optimization in antidiabetic drug discovery. Research Journal of Pharmacy and Technology. 2012; 5(8): 1025-33.
57. Jurga AM, Rojewska E, Piotrowska A, Makuch W, Pilat D, Przewlocka B, et al. Blockade of toll‐like receptors (TLR2, TLR4) attenuates pain and potentiates buprenorphine analgesia in a rat neuropathic pain model. Neural Plasticity. 2016; 2016(1): 5238730. 10.1155/2016/5238730
58. Bunyan IA, Umran BJ, Salman ZK. Analyzing the correlation of TLR-4 Asp299Gly and Thr399Ile polymorphism in women with Bacterial Vaginosis in Hillah city. Research Journal of Pharmacy and Technology. 2017; 10(12): 4178-82. 10.5958/0974-360X.2017.00762.4